Neuropsychiatric Testing Provides Objective Insight Into Beneficial Effects Of Intravenous Immunoglobulins In Patients With Pediatric Acute-Onset Neuropsychiatric Syndrome

Abstract

Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) is defined by acute beginning of diverse neuropsychiatric symptoms, likely in the setting of underlying immune dysfunction. Thus, immunomodulatory interventions have a crucial therapeutic role, but objective post-treatment evaluations remain challenging given disease complexity. We used standardized neuropsychiatric testing to assess how intravenous immunoglobulins (IVIG) impact cognitive function.